CRIS Current Research Information System

ZINZANI, PIER LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.211
EU - Europa 13.656
AS - Asia 5.051
AF - Africa 764
SA - Sud America 49
Continente sconosciuto - Info sul continente non disponibili 22
OC - Oceania 22
Totale 39.775
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.152
GB - Regno Unito 4.196
SE - Svezia 2.212
CN - Cina 2.090
DE - Germania 1.978
IT - Italia 1.678
VN - Vietnam 1.671
IN - India 875
UA - Ucraina 718
IE - Irlanda 655
FR - Francia 576
RU - Federazione Russa 544
ZA - Sudafrica 339
EE - Estonia 308
TG - Togo 202
CH - Svizzera 170
JO - Giordania 126
HR - Croazia 125
FI - Finlandia 112
CI - Costa d'Avorio 98
BG - Bulgaria 86
NG - Nigeria 67
BE - Belgio 61
CA - Canada 53
JP - Giappone 53
SC - Seychelles 52
IR - Iran 48
PL - Polonia 46
GR - Grecia 38
HK - Hong Kong 36
NL - Olanda 34
AT - Austria 32
ES - Italia 29
LB - Libano 29
BR - Brasile 23
SG - Singapore 21
TR - Turchia 19
EU - Europa 18
RO - Romania 16
AU - Australia 15
CL - Cile 15
UZ - Uzbekistan 14
CZ - Repubblica Ceca 12
KR - Corea 9
MY - Malesia 9
DK - Danimarca 8
NZ - Nuova Zelanda 7
ID - Indonesia 6
PE - Perù 6
PH - Filippine 6
PK - Pakistan 6
TW - Taiwan 6
IL - Israele 5
MX - Messico 5
A2 - ???statistics.table.value.countryCode.A2??? 4
TN - Tunisia 4
EC - Ecuador 3
HU - Ungheria 3
MK - Macedonia 3
SM - San Marino 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AM - Armenia 2
BD - Bangladesh 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BO - Bolivia 2
LA - Repubblica Popolare Democratica del Laos 2
NO - Norvegia 2
PT - Portogallo 2
RS - Serbia 2
SA - Arabia Saudita 2
BY - Bielorussia 1
BZ - Belize 1
GE - Georgia 1
GH - Ghana 1
IQ - Iraq 1
KW - Kuwait 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MT - Malta 1
MU - Mauritius 1
OM - Oman 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 39.775
Salva come PNG Salva come JPEG
Città #
Southend 3.817
Fairfield 3.121
Chandler 1.648
Ashburn 1.633
Woodbridge 1.504
Houston 1.458
Wilmington 1.360
Seattle 1.341
Cambridge 1.104
Princeton 1.089
Ann Arbor 1.038
Dong Ket 762
Dublin 655
Jacksonville 414
Westminster 412
Nanjing 395
Berlin 331
Padova 329
Bologna 293
Jinan 211
Lomé 202
San Diego 193
Saint Petersburg 192
Shenyang 181
New York 180
Beijing 155
Changsha 135
Hebei 134
Bern 127
Amman 126
Nanchang 123
Bremen 119
Turin 110
Boardman 108
Helsinki 103
Milan 103
Tianjin 101
Abidjan 98
Mülheim 94
Redmond 93
Jiaxing 87
Redwood City 85
Sofia 82
Des Moines 80
Falls Church 80
Olalla 78
Dearborn 76
Zhengzhou 73
Hangzhou 69
Norwalk 68
Los Angeles 66
Abeokuta 65
Brussels 56
Florence 54
Taizhou 54
Haikou 47
Mahé 47
Ningbo 45
Guangzhou 44
Medford 44
Tokyo 38
Bühl 36
London 36
Taiyuan 36
Verona 35
San Venanzo 33
Toronto 32
Paris 29
Rome 28
Lanzhou 25
Warsaw 25
Hong Kong 23
Fuzhou 21
Chicago 20
Phoenix 19
Frankfurt Am Main 18
Kunming 18
Zanjan 18
Vienna 17
Andover 15
Lausanne 15
San Francisco 15
São Paulo 15
Wayne 15
Boydton 14
Buffalo 14
Istanbul 14
Leawood 14
Rijeka 14
Frankfurt am Main 13
Parma 13
Fremont 12
Monmouth Junction 12
Mountain View 12
Naples 12
Amsterdam 11
Groningen 11
Pune 11
Cedar Knolls 10
Hefei 10
Totale 27.671
Salva come PNG Salva come JPEG
Nome #
18F-FDG PET early after radiotherapy in lymphoma patients. 228
Biology and treatment of follicular lymphoma. 190
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 188
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 187
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 174
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 172
CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. 171
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 170
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 166
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 165
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. 159
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 158
18 F-FDG PET in malignant lymphoma: significance of positive findings 157
Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma – Authors' reply 157
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens 153
Consensus conference on the management of tumor lysis syndrome. 149
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 145
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. 145
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 145
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 144
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 142
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 142
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 141
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 140
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 138
A multicenter phase II trial (SAKK 36/06) of single-agent Everolimus(RAD001) in patients with relapsed or refractory mantle cell lymphoma. 138
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 138
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 137
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. 136
Expression of CD52 in peripheral T-cell lymphoma. 136
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 136
Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. 134
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 134
Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients 134
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 133
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 133
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 133
Primary non-hodgkin’s lymphoma of bone: treatment and analysis of prognostic factors for stage I and stage II 133
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 132
CDKN1B/P27 expression in peripheral T-cell lymphoma not otherwise specified 131
CD30 expression in peripheral T-cell lymphomas 131
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 131
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 130
Anaplastic Large Cell Lymphoma: a critical reappraisal 129
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 129
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. 127
An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis. A case report and a review of literature. 127
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 126
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 125
Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma. 125
Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program 125
Lymphoma: diagnosis, staging, natural history, and treatment strategies. 124
RALE051: a novel established cell line of sporadic Burkitt lymphoma 124
Histopathology of B-cell chronic lymphocytic leukemia. 122
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. 122
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 122
Linfomi a cellule T periferiche NAS: nuovo indice prognostico. 121
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 121
Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: a diagnostic and therapeutic challenge. 120
Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial 120
The role of mitoxantrone in the treatment of indolent lymphomas. 119
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. 119
Angioimmunoblastic T-Cell Lymphoma 119
CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. 119
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 118
Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis 118
Autologous hematopoietic stem cell transplantation in Non-Hodgkin's lymphomas. 117
Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients. 117
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology. 116
Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. 115
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 115
Gastric MALT Lymphoma in a Sleeve Gastrectomy Specimen: Case Report and Literature Review 114
Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy. 114
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study 114
Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper 113
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 112
Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. 112
Bendamustine: role and evidence in lymphoma therapy, an overview. 112
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 111
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). 111
BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia 111
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS 111
Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. 110
Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials 110
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 110
SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. 110
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 110
ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK(+) ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project 110
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 110
Targeted molecular therapy in peripheral T-cell lymphomas 109
CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies? 109
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies 109
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. 108
Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure 108
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial 108
Leukocytoclastic vasculitis associated with hairy cell leukemia at diagnosis: A case report and review of the literature 108
The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients 108
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 108
Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. 107
Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. 107
Totale 13.031
Salva come PNG Salva come JPEG
Categoria #
all - tutte 105.349
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 105.349
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019972 0 0 0 0 0 0 0 0 0 382 177 413
2019/202012.300 1.637 300 106 699 1.290 1.327 1.504 1.640 1.751 817 461 768
2020/20216.298 1.219 467 181 233 147 429 81 325 673 278 317 1.948
2021/20228.269 901 251 567 737 812 444 178 671 307 477 1.593 1.331
2022/20238.447 973 1.102 503 1.028 698 601 280 540 1.390 301 606 425
2023/20242.412 180 449 201 270 223 374 177 180 98 260 0 0
Totale 41.090